Skip to main content

The nuclear medicine department of the Institut Jules Bordet offers patients diagnostic tests of the functional or molecular type, as well as treatments with targeted molecular radiotherapy.  

The diagnostic tests differ from those carried out in the Radiology Department in that they involve the intravenous administration of substances labelled with radioactive isotopes, which specifically make it possible to identify the functionality or characteristic of an organ or of the cancer.

Therapeutic applications in nuclear medicine (often called “molecular radiotherapy”) use the same type of substance (tracer) specifically targeting the cancer tissue, but this substance is labelled with radioactive isotopes which emit therapeutic particles of the beta or alpha type enabling the destruction of the diseased cells.

Research projects

Project 1

Predicting the therapeutic result of 177Lu-octreotate (PRRT) using hybrid imaging in the case of refractory neuroendocrine tumours (LuMen)

Project 2

Somatostatin receptors imaging in relapsing and refractory multiple myeloma patients.

Project 3

Phase II prospective, multicentre study evaluating the utility of a an HER2-PET/CT combined with an FDG-PET/CT in identifying HER2 negative lesions that will not benefit from a new targeted treatment against HER2 : T-DM1 (ZEPHIR)
  • Project leader(s): Géraldine GebhartPatrick Flamen
  • Collaboration(s): Roche, Belgian and Dutch university hospital and centres  
  • Financing/Support : Roche

Project 4

Selective Internal Radiotherapy (SIRT) of colorectal hepatic metastases: prediction of the response

Project 5

An open-label study in which the diagnostic performance of an imaging agent coupled with a small amount of radioactive material is investigated for detection of clear cell renal carcinoma using CT/PET scans (ZIRCON study)

Project 6

MOLECULAR BIOMARKERS IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER: PSMA EXPRESSION, METABOLIC ACTIVITY, AND CIRCULATING CELL-FREE DNA.

Our team

Head of Department
Prof Patrick Flamen

The team
Dr Carlos Artigas
Assistant Head of Clinic
Dr Géraldine GebhartAssistant Head of Clinic
Dr Ioannis KarfisAssistant Head of Clinic
Dr Elçin ÖzalpAssistant Head of Clinic
Dr Erwin WoffAssistant Head of Clinic
Dr Ivan Duran Derijckere, Resident

Radiophysicists (Department of Radiophysics)
Clémentine Marin, Radiophysicist 
Marie Christiane Yimo-Wadje (Physics control)
Gwennaëlle MarinRadiophysicist
Bruno Vanderlinden

Radiopharmacy
Prof Ghanem Ghanem

Zéna Wimana
Maxime Renguet
Adriana De Matos
Sara Coelho

Coordination of radionuclide treatments and thyroid checkups
Marie-Noëlle Gheeraert
Pauwel Thijs 
(thyroid cancer)

CoreLab molecular imaging (ORILAB)
Thomas Guiot, Ing

Research Unit
Zéna Wimana, Radiopharmacy/pre-clinical imaging
Wendy Delbart,
PhD Student/Research Assistant
Loubna Taraji Schiltz, Clinical Study Coordinator
Hugo Levillain, PhD Student in Medical Physics
Gabriela Critchi, Research Assistant

Secretaries
Jessie Toussaint
Anandi Henriet
Alyssa Hammouda (PET-Scan)

20/01/2020

 Scientific publications

Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer.

Authors : Bregni G, Vandeputte C, Pretta A, Senti C, Trevisi E, Acedo Reina E, Kehagias P, Liberale G, Moretti L, Bali MA, Demetter P, Flamen P, Carrasco J, DHondt L, Geboes K, Gokburun Y, Peeters M, Van den Eynde M, Van Laethem JL, Vergauwe P, Chapot CA, Buyse M, Deleporte A, Hendlisz A, Sclafani F
Year : 2021
Journal : Acta oncologica
Pages : 1-5

International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres.

Authors : Levillain H, Bagni O, Deroose CM, Dieudonné A, Gnesin S, Grosser OS, Kappadath SC, Kennedy A, Kokabi N, Liu DM, Madoff DC, Mahvash A, Martinez de la Cuesta A, Ng DCE, Paprottka PM, Pettinato C, Rodríguez-Fraile M, Salem R, Sangro B, Strigari L, Sze DY, de Wit van der Veen BJ, Flamen P
Year : 2021
Journal : Eur J Nucl Med Mol Imaging

Correction to: Combined quality and dose-volume histograms for assessing the predictive value of <sup>99m</sup>Tc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer.

Authors : Levillain H, Burghelea M, Derijckere ID, Guiot T, Gulyban A, Vanderlinden B, Vouche M, Flamen P, Reynaert N
Year : 2021
Journal : EJNMMI Phys
Volume : 8
Pages : 9

131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.

Authors : Jungels C, Karfis I
Year : 2021
Journal : Curr Opin Oncol
Volume : 33
Pages : 33-39

Absence of residual fluorescence in the surgical bed at near-infrared fluorescence imaging predicts negative margins at final pathology in patients treated with breast-conserving surgery for breast cancer.

Authors : Pop FC, Veys I, Vankerckhove S, Barbieux R, Chintinne M, Moreau M, Donckier V, Larsimont D, Bourgeois P, Liberale G
Year : 2021
Journal : Eur J Surg Oncol
Volume : 47
Pages : 269-275